Nectin Therapeutics News
7 articles
growth-positive
Israeli biotech co Nectin Therapeutics raises $10m
Guangzhou-Israel Biotechnology Fund (GIBF) has invested $10 million in Israeli biotechnology company Nectin Therapeutics. Nectin is developing targeted immunotherapies for resistance to approved immune oncology treatments. The investment will be used to continue the development of Nectins portfolio of novel immuno-oncology products, including the advancement of Nectins ongoing NTX1088 global Phase 1 clinical trial targeting PVR and the preclinical development of its anti-drug conjugate (ADC) portfolio.
Investment
Myeloma Investment Fund Invests in Nectin Therapeutics to Evaluate Nectin's Anti-PVR Lead Drug Candidate as a Treatment for Multiple Myeloma
growth-positive
Nectin Therapeutics to Collaborate with Merck on a Clinical Trial of Anti-PVR Antibody NTX1088 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Locally Advanced and Metastatic Solid Tumors | BioSpace
Nectin Therapeutics has entered into a clinical trial collaboration agreement with Merck to evaluate the safety and efficacy of its novel anti-PVR antibody, NTX1088, in combination with Mercks anti-PD1 therapy, KEYTRUDA, in patients with solid tumors. NTX1088 aims to restore the antitumor immune activity of DNAM1 by blocking PVR, a protein associated with resistance to immune checkpoint inhibitors. The phase 1 trial with NTX1088 has already been initiated. The collaboration represents a promising new therapy for cancer patients and a milestone for Nectin Therapeutics.
Partners
growth-positive
Israeli co Nectin Therapeutics raises $25m
Nectin Therapeutics, an Israeli biotechnology company, has completed a $25 million Series A financing round led by IBF and Peregrine Ventures. The funding will be used to support the ongoing clinical evaluation of NTX1088, the companys first-in-class PVR (CD155) blocker, and to further advance its pipeline of targeted immunotherapies and Antibody Drug Conjugates (ADCs). Nectin is developing novel targeted immunotherapies to address resistance to approved immuno-oncology treatments. The company has also announced the dosing of the first patient in its Phase I clinical trial of NTX1088, which is being conducted at The University of Texas MD Anderson Cancer Center. Nectin aims to overcome the limitations of existing IO therapies and provide new treatment options for patients with difficult-to-treat cancers.
InvestmentExpand
growth-positive
Nectin Therapeutics Announces Initiation of Patient Dosing in Phase 1 Clinical Trial of NTX1088, First-in-Class Anti-PVR Targeted Immunotherapy for Treatment of Patients with Advanced Solid Tumors
Nectin Therapeutics has announced the dosing of the first patient in its Phase 1 clinical trial of NTX1088, a first-in-class PVR (CD155) blocker for cancer patients with advanced solid tumors. The trial is being conducted at MD Anderson Cancer Center with an investment from the Cancer Focus Fund. Nectin has also extended its Series A financing to over $25 million, with IBF and Peregrine Ventures leading the round. The funding will be used to support the ongoing clinical evaluation of NTX1088 and advance the companys pipeline of targeted immunotherapies and Antibody Drug Conjugates (ADCs). NTX1088 aims to restore DNAM-1 expression on immune cells and stimulate an anti-tumor immune response. PVR is overexpressed in many solid tumors and is associated with resistance to PD-1 and PD-L1 blockade. The Phase 1 trial will include up to 90 patients treated with NTX1088 as a monotherapy and in combination with a PD-1 blocker.
InvestmentExpand
growth-positive
Nectin Therapeutics Announces $5.4 Million Investment from Cancer Focus Fund to Support Phase 1 Study of First-in-Class Anti-PVR Targeted Immunotherapy
Nectin Therapeutics and Cancer Focus Fund have announced a $5.4 million investment to finance a Phase 1 clinical trial of Nectins PVR blocker, NTX1088, in cancer patients with locally advanced and metastatic solid tumors. NTX1088 is a monoclonal antibody that blocks the signaling of immune checkpoint receptors, resulting in increased anti-tumor immune effects. The investment will support the clinical study at MD Anderson, and Cancer Focus Fund will receive equity and future payments based on certain milestones. The Phase 1 trial is expected to begin enrolling patients in mid-2022.
Investment
growth-positive
Israeli immuno-oncology co Nectin raises $6m
Nectin Therapeutics, an Israeli immuno-oncology biotherapies company, has completed the first $6 million closing of a financing round led by aMoon Velocity and with the participation of Integra Holdings. The company plans to raise a total of $15 million in the financing round. Nectin Therapeutics develops antibodies that inhibit the activity of Nectin family proteins, enhancing the immune systems ability to fight cancers. The investment in Nectin Therapeutics aims to advance and improve the potential of novel immuno-oncology antibodies.
Investment
